which NGF deprivation or Aβ treatment leads successively to Akt inactivation, FoxO activation, and suppression of miR-21 levels with consequent elevation of Cdc25A. Normally, Akt phosphorylates FoxO transcription factors, which limits them to the cytosol ( Figure 1 ). Aβ treatment inhibits Akt signalling in neurons and Akt activity is diminished in brains of AD patients and of APP transgenic mice. 7, 8 NGF deprivation also rapidly decreases Akt phosphorylation/activity. 9 When Akt signalling is suppressed, 10 FoxO proteins are dephosphorylated and translocate to the nucleus where they are transcriptionally active. 3, 8, 9 We show that FoxO3a downregulates miR-21 (a microRNA that usually suppresses Cdc25A expression) thereby upregulating Cdc25A in Aβ-treated neurons. 6 Moreover, a miR-21 mimic was sufficient to block Cdc25A mRNA and protein induction by Aβ. Thus our study places Cdc25A upstream of Cdk4 activation and subsequent events in the apoptotic neuronal death pathway and identifies a set of signaling events by which NGF deprivation or Aβ exposure regulate cellular Cdc25A levels and activity, leading to neuron death ( Figure 1) .
A previous study reported that camptothecin-induced DNA damage in cultured neurons activates Cdc25A and that inhibition or knockdown of Cdc25A blocks Cdk4 activation and Rb phosphorylation as well as cell death, thus linking Cdc25A to the apoptotic cell cycle pathway. 11 However, in contrast to Aβ or NGF deprivation, camptothecin did not change Cdc25A levels (and therefore not likely the FoxOmiR21 pathway), but rather was correlated with loss of activity of the checkpoint 1 kinase (Chk1).
11 Therefore, although it appears that distal effectors of the neuronal apoptotic cell cycle pathway are similar for different apoptotic stimuli, multiple mechanisms may exist to initiate the pathway via Cdc25A.
Ours is the first report to identify Cdc25A as a required upstream activator of the apoptotic cell cycle pathway in trophic factor-deprived neurons and that its levels after Aβ treatment are elevated by a pathway involving FoxOs and miR-21. 6 In the case of Aβ, our findings are consistent with the report that neurons in post-mortem brains from AD patients have elevated Cdc25A levels and that brain tissue from AD patients has higher Cdc25A phosphatase activity compared to non-AD brains. 12 Also, Kruman et al. 13 described a 3-4-fold increase in Cdc25A protein in Aβ-treated cortical neuron cultures. Thus, our study favours a mechanism in which Aβ elevates Cdc25A expression via FoxO-miR21 signalling and our data clearly identify Cdc25A as a required player in Aβ-induced neuron death. In summary, our study reveals that Cdc25A is elevated, activated and has an essential role in neuronal cell death evoked by apoptotic stimuli relevant to normal development and to AD. Because Cdc25A is an inhibitable enzyme, our study identifies Cdc25A as a potential target to block pathologic neuron degeneration and death in AD and other pathologies in which the neuronal apoptotic cell cycle pathway is activated. In support of this idea, a selective Cdc25A inhibitor has been shown to be effective in several non-neuronal experimental disease models and without reported toxicity. 
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